Zetomipzomib API Manufacturers
compare suppliers & get competitive offers
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Zetomipzomib is listed?
Join our notification list by following this page.
Join our notification list by following this page.
List your company
Are you a supplier of Zetomipzomib or other APIs and are you looking to list your company on Pharmaoffer?
Click the button below to find out more
Click the button below to find out more
Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?
Click the button below to switch over to the contract services area of Pharmaoffer.
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Zetomipzomib API 1629677-75-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Zetomipzomib. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Zetomipzomib
- Synonyms:
- (2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide
- Cas Number:
- 1629677-75-3
- DrugBank number:
- DB16070
- Unique Ingredient Identifier:
- O4BT6C02M2
General Description:
Zetomipzomib, identified by CAS number 1629677-75-3, is a notable compound with significant therapeutic applications. Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis).
Categories:
Zetomipzomib is categorized under the following therapeutic classes: Oxazines. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
